Navigation Links
Targanta Study Shows Oritavancin Treatment Effective in a Mouse,Model of Anthrax

deaths and 125,000 hospitalizations.

About Oritavancin

Oritavancin, Targanta's lead product candidate, is a semi-synthetic lipoglycopeptide antibiotic with rapid in vitro bactericidal activity against a broad spectrum of serious gram-positive pathogens, including multi-resistant strains. Oritavancin's multiple targets and mechanisms of action work against the development of resistant strains, which is important when treating serious gram-positive infections. To date, over 1500 individuals have received oritavancin in clinical trials, including two large multi-national Phase 3 studies in complicated skin and skin structure infections (cSSSI) performed by former developers Eli Lilly and Company and InterMune, Inc. Targanta expects to file a New Drug Application (NDA) for oritavancin for the treatment of cSSSI with the U.S. Food and Drug Administration in the first quarter of 2008.

About Targanta Therapeutics Corporation

Targanta Therapeutics Corporation is a privately held biopharmaceutical company developing and commercializing innovative antibiotics to treat serious infections (either treated or acquired) in the hospital and other institutional settings. Its pipeline includes a number of antibacterial agents in various stages of development. The company has operations in Cambridge, MA, Indianapolis, IN, Montreal, Quebec, and Toronto, Ontario, Canada. For further information about Targanta, visit the company website, http://www.targanta.com.

About U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)

USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Biological Defense Research Program, and plays a key role in national defense and in infectious disease research. The Institute's mission is to conduct basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and d
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:8/25/2008)...vention and Treatment Strategies--, PHILADELPHIA,...e,discovered gene mutations that are the main caus... neuroblastoma. In addition, the researchers found...n high-risk forms of,non-inherited neuroblastoma, ...very enables us to offer the first genetic tests t...
(Date:8/25/2008)...atient calls it a ,miracle, LATHAM, N.Y., Aug. 2...age Guided Radiation Therapy program at Community ...cancer patients using RapidArc(TM),radiotherapy te..., an,advancement that delivers a highly-precise im...) treatment in two minutes or less., RapidArc tre...
(Date:8/25/2008)... CLL Retreatment and Japanese Development Studies ...N, Denmark, August 25 /- Ge...ofatumumab in chronic lymphocytic,leukemia and non...nced today plans to begin four studies of,ofatumum...cular,non-Hodgkin,s lymphoma (NHL) this year., "G...
(Date:8/22/2008)...ust 22 /-, - Dangerous Bacteria Infe...etimes something well-tried can also be innovative... to be very antimicrobial. This,ability is now pla...gerous,hospital germs. In a worldwide noted field ...c in Wandsbek in Hamburg, Germany, was equipped wi...
Breaking Medicine Technology:Gene That Causes Childhood Cancer Neuroblastoma Is Found 2Gene That Causes Childhood Cancer Neuroblastoma Is Found 3Gene That Causes Childhood Cancer Neuroblastoma Is Found 4Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology 2Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology 3Genmab Announces Upcoming Ofatumumab Studies 2Genmab Announces Upcoming Ofatumumab Studies 3Genmab Announces Upcoming Ofatumumab Studies 4Copper Eliminates Resistant Hospital Germs in a Worldwide Field Test 2Copper Eliminates Resistant Hospital Germs in a Worldwide Field Test 3Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference 714 1Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference 714 2Lexicon Pharmaceuticals to Present at the UBS Global Life Sciences Conference 712 1Lexicon Pharmaceuticals to Present at the UBS Global Life Sciences Conference 712 2Beaumont Patients 1st to get Next Generation of Radiation Treatment 337 1Beaumont Patients 1st to get Next Generation of Radiation Treatment 337 2Repeat steroids to premature infants linked to cerebral palsy 1654 1Repeat steroids to premature infants linked to cerebral palsy 1654 2
...Selective Anti-VEGF Antibodies Inhibited Tumor Gro...Cancer Model -, , - Peregrine,s Antibodies that Se...lly Have Advantages over Non-Selective Approaches ... Fully Human,Antibody Support , Advancing Peregrin...LOS ANGELES and TUSTIN, Calif., April 16, 2007,/PR...
...pril 16, 2007 /PRNewswire/ -- Expression,Genetics,...,clinical study evaluating the Company,s lead drug...University of Alabama at,Birmingham and , evaluate... biological activity of the EGEN-001 in 13 patient...r. The product,utilizing the Company,s proprietar...
Other Medicine Technology:Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 2Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 3Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 4Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 5Expression Genetics, Inc. Announces Successful Completion of Phase,I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer 2Expression Genetics, Inc. Announces Successful Completion of Phase,I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer 3Expression Genetics, Inc. Announces Successful Completion of Phase,I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer 4
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...A new dryer that is capable of eliminating parasit... from hair with a single half hour treatment is mu...ches claim researchers. The dryer capable of dryi... lower temperature than that of a regular hair dry...
...The Pakistan Medical Association (PMA) plans to mo...ast bowlers Shoaib Akhtar and Mohammed Asif.// "T...tside world and the International Cricket Council ...was not meted out to the two," PMA president Umer ...
...'Sexual Harassment' at the workplace faced by wome...days and many of them are not ready to come out op...lkata, West Bengal, with 135 in-depth interviews o...d two private hospitals over a period of 11 months...
...Russia a country known for its lax regulations reg...rowning themselves in liquor without any person// ... So it comes as little surprise when recent estima...ie annually from disorders which are linked to alc...
Other Medicine News:Health News:Lice now dried to death by novel dryer 2Health News:Doctors, Nurses Face Sexual Harassment At Work Place 2
Inquire
Pkg qty: box of 2 bags pack of 25 (Pack = Zippered Bag)
Adhesive tape sheets for sealing multiwell plates and blocks;
Microwell Plate Accessories
Medicine Products: